BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huber M, Brehm CU, Gress TM, Buchholz M, Alashkar Alhamwe B, von Strandmann EP, Slater EP, Bartsch JW, Bauer C, Lauth M. The Immune Microenvironment in Pancreatic Cancer. Int J Mol Sci 2020;21:E7307. [PMID: 33022971 DOI: 10.3390/ijms21197307] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Kothari A, Flick MJ. Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2021;22:5138. [PMID: 34066284 DOI: 10.3390/ijms22105138] [Reference Citation Analysis]
2 Zhang K, Xu PL, Li YJ, Dong S, Gao HF, Chen LY, Chen H, Chen Z. Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer. BMC Genom Data 2022;23:5. [PMID: 35012444 DOI: 10.1186/s12863-021-01019-5] [Reference Citation Analysis]
3 Vance K, Alitinok A, Winfree S, Jensen-Smith H, Swanson BJ, Grandgenet PM, Klute KA, Crichton DJ, Hollingsworth MA. Machine learning analyses of highly-multiplexed immunofluorescence identifies distinct tumor and stromal cell populations in primary pancreatic tumors. Cancer Biomark 2022;33:219-35. [PMID: 35213363 DOI: 10.3233/CBM-210308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Opitz FV, Haeberle L, Daum A, Esposito I. Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia. Cancers 2021;13:6188. [DOI: 10.3390/cancers13246188] [Reference Citation Analysis]
5 Park R, Coveler AL, Cavalcante L, Saeed A. GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties. Biology (Basel) 2021;10:610. [PMID: 34356465 DOI: 10.3390/biology10070610] [Reference Citation Analysis]
6 Zhang J, Tian Y, Mo S, Fu X. Overexpressing PLOD Family Genes Predict Poor Prognosis in Pancreatic Cancer. IJGM 2022;Volume 15:3077-96. [DOI: 10.2147/ijgm.s341332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kokkinos J, Jensen A, Sharbeen G, McCarroll JA, Goldstein D, Haghighi KS, Phillips PA. Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer? Cancers (Basel) 2021;13:2427. [PMID: 34067833 DOI: 10.3390/cancers13102427] [Reference Citation Analysis]
8 Ponath V, Hoffmann N, Bergmann L, Mäder C, Alashkar Alhamwe B, Preußer C, Pogge von Strandmann E. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles. Int J Mol Sci 2021;22:2189. [PMID: 33671836 DOI: 10.3390/ijms22042189] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Zhang W, Xing J, Liu T, Zhang J, Dai Z, Zhang H, Wang D, Tang D. Small extracellular vesicles: from mediating cancer cell metastasis to therapeutic value in pancreatic cancer. Cell Commun Signal 2022;20:1. [PMID: 34980146 DOI: 10.1186/s12964-021-00806-y] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Seibold T, Waldenmaier M, Seufferlein T, Eiseler T. Small Extracellular Vesicles and Metastasis-Blame the Messenger. Cancers (Basel) 2021;13:4380. [PMID: 34503190 DOI: 10.3390/cancers13174380] [Reference Citation Analysis]
11 Group Young Researchers In Inflammatory Carcinogenesis, Wandmacher AM, Mehdorn AS, Sebens S. The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. Cancers (Basel) 2021;13:4932. [PMID: 34638420 DOI: 10.3390/cancers13194932] [Reference Citation Analysis]
12 Toledano-Fonseca M, Cano MT, Inga E, Gómez-España A, Guil-Luna S, García-Ortiz MV, Mena-Osuna R, De la Haba-Rodriguez JR, Rodríguez-Ariza A, Aranda E. The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer. Cancers (Basel) 2021;13:1210. [PMID: 33802006 DOI: 10.3390/cancers13061210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chen ZG, Wang Y, Fong WP, Hu MT, Liang JY, Wang L, Li YH. A quantitative score of immune cell infiltration predicts the prognosis in pancreatic ductal adenocarcinoma. Int Immunopharmacol 2021;98:107890. [PMID: 34174701 DOI: 10.1016/j.intimp.2021.107890] [Reference Citation Analysis]
14 El Haddaoui H, Brood R, Latifi D, Oostvogels AA, Klaver Y, Moskie M, Mustafa DA, Debets R, van Eijck CHJ. Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program. Cancers (Basel) 2022;14:1377. [PMID: 35326528 DOI: 10.3390/cancers14061377] [Reference Citation Analysis]
15 Wandmacher AM, Letsch A, Sebens S. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. Cancers (Basel) 2021;13:4235. [PMID: 34439389 DOI: 10.3390/cancers13164235] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sivakumar S, Abu-Shah E, Ahern DJ, Arbe-Barnes EH, Jainarayanan AK, Mangal N, Reddy S, Rendek A, Easton A, Kurz E, Silva M, Soonawalla Z, Heij LR, Bashford-Rogers R, Middleton MR, Dustin ML. Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer. Cancers (Basel) 2021;13:1776. [PMID: 33917832 DOI: 10.3390/cancers13081776] [Reference Citation Analysis]
17 Zhang F, Wang Y, Yang F, Zhang Y, Jiang M, Zhang X. The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study. CMAR 2022;Volume 14:535-46. [DOI: 10.2147/cmar.s349442] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hassan Z, Schneeweis C, Wirth M, Müller S, Geismann C, Neuß T, Steiger K, Krämer OH, Schmid RM, Rad R, Arlt A, Reichert M, Saur D, Schneider G. Important role of Nfkb2 in the KrasG12D-driven carcinogenesis in the pancreas. Pancreatology 2021;21:912-9. [PMID: 33824054 DOI: 10.1016/j.pan.2021.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Narayanan S, Vicent S, Ponz-sarvisé M. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem? Front Cell Dev Biol 2021;9:787249. [DOI: 10.3389/fcell.2021.787249] [Reference Citation Analysis]
20 Cong H, Gao J, Wang Q, Du M, Li H, Li Q, Li J, Liang Y, Zhao D, Yang H, Gan Y, Tu H. Increased Expression of Mitochondrial UQCRC1 in Pancreatic Cancer Impairs Antitumor Immunity of Natural Killer Cells via Elevating Extracellular ATP. Front Oncol 2022;12:872017. [DOI: 10.3389/fonc.2022.872017] [Reference Citation Analysis]
21 Jaworek C, Verel-Yilmaz Y, Driesch S, Ostgathe S, Cook L, Wagner S, Bartsch DK, Slater EP, Bartsch JW. Cohort Analysis of ADAM8 Expression in the PDAC Tumor Stroma. J Pers Med 2021;11:113. [PMID: 33578644 DOI: 10.3390/jpm11020113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Romano R, Picca A, Eusebi LHU, Marzetti E, Calvani R, Moro L, Bucci C, Guerra F. Extracellular Vesicles and Pancreatic Cancer: Insights on the Roles of miRNA, lncRNA, and Protein Cargos in Cancer Progression. Cells 2021;10:1361. [PMID: 34205944 DOI: 10.3390/cells10061361] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Greene MK, Johnston MC, Scott CJ. Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance. Cancers (Basel) 2021;13:6175. [PMID: 34944794 DOI: 10.3390/cancers13246175] [Reference Citation Analysis]
24 Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, de Vries JJJ, van den Tol MP, Bruynzeel AME, Streppel MM, Wilmink JW, van der Vliet HJ, Meijerink MR, Scheffer HJ, de Gruijl TD. Pancreatic Cancer and Immunotherapy: A Clinical Overview. Cancers (Basel) 2021;13:4138. [PMID: 34439292 DOI: 10.3390/cancers13164138] [Reference Citation Analysis]
25 Kamgar M, Chakrabarti S, Shreenivas A, George B. Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. Surg Oncol Clin N Am 2021;30:673-91. [PMID: 34511189 DOI: 10.1016/j.soc.2021.06.004] [Reference Citation Analysis]
26 Mollinedo F, Gajate C. Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer. Cancers (Basel) 2021;13:4173. [PMID: 34439330 DOI: 10.3390/cancers13164173] [Reference Citation Analysis]
27 Waldenmaier M, Seibold T, Seufferlein T, Eiseler T. Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication. Cancers (Basel) 2021;13:4844. [PMID: 34638330 DOI: 10.3390/cancers13194844] [Reference Citation Analysis]
28 Cai W, Bao W, Chen S, Yang Y, Li Y. Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma. Cancer Cell Int 2021;21:698. [PMID: 34930261 DOI: 10.1186/s12935-021-02378-w] [Reference Citation Analysis]
29 Shi J, Shen X, Kang Q, Yang X, Denzinger M, Kornmann M, Traub B. Loss of Interleukin-13-Receptor-Alpha-1 Induces Apoptosis and Promotes EMT in Pancreatic Cancer. Int J Mol Sci 2022;23:3659. [PMID: 35409019 DOI: 10.3390/ijms23073659] [Reference Citation Analysis]
30 Oshima Y, Sano M, Kajiwara I, Ichimaru Y, Itaya T, Kuramochi T, Hayashi E, Kim J, Kitajima O, Masugi Y, Masamune A, Ijichi H, Ishii Y, Suzuki T. Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma. Br J Anaesth 2022:S0007-0912(21)00873-4. [PMID: 35120712 DOI: 10.1016/j.bja.2021.12.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Cook L, Sengelmann M, Winkler B, Nagl C, Koch S, Schlomann U, Slater EP, Miller MA, von Strandmann EP, Dörsam B, Preußer C, Bartsch JW. ADAM8-Dependent Extracellular Signaling in the Tumor Microenvironment Involves Regulated Release of Lipocalin 2 and MMP-9. Int J Mol Sci 2022;23:1976. [PMID: 35216088 DOI: 10.3390/ijms23041976] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Zhu Q, Qiao G, Huang L, Xu C, Guo D, Wang S, Zhao J, Song Y, Liu B, Chen Z, Yang Z, Yuan Y. Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma. Front Oncol 2022;12:837560. [DOI: 10.3389/fonc.2022.837560] [Reference Citation Analysis]
33 Ostios-Garcia L, Villamayor J, Garcia-Lorenzo E, Vinal D, Feliu J. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. World J Gastroenterol 2021; 27(40): 6775-6793 [PMID: 34790007 DOI: 10.3748/wjg.v27.i40.6775] [Reference Citation Analysis]
34 Fei X, Kong L, Shi C, Wang G, Liu C, Wang C, Liu P, Tan X, Bu D. Identification of Prognosis-Related Molecular Subgroups and Construction of a Prognostic Prediction Model Using Immune-Related Genes in Pancreatic Cancer. Journal of Oncology 2022;2022:1-21. [DOI: 10.1155/2022/7117014] [Reference Citation Analysis]
35 Cattolico C, Bailey P, Barry ST. Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC. Front Cell Dev Biol 2022;10:816517. [PMID: 35273962 DOI: 10.3389/fcell.2022.816517] [Reference Citation Analysis]
36 Krishnan SN, Mohammed S, Frankel TL, Rao A. GaWRDenMap: a quantitative framework to study the local variation in cell-cell interactions in pancreatic disease subtypes. Sci Rep 2022;12:3708. [PMID: 35260589 DOI: 10.1038/s41598-022-06602-z] [Reference Citation Analysis]
37 Chakrabarti S, Kamgar M, Mahipal A. Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Cancers (Basel) 2022;14:2588. [PMID: 35681565 DOI: 10.3390/cancers14112588] [Reference Citation Analysis]
38 Damiani V, Cufaro MC, Fucito M, Dufrusine B, Rossi C, Del Boccio P, Federici L, Turco MC, Sallese M, Pieragostino D, De Laurenzi V. Proteomics Approach Highlights Early Changes in Human Fibroblasts-Pancreatic Ductal Adenocarcinoma Cells Crosstalk. Cells 2022;11:1160. [PMID: 35406724 DOI: 10.3390/cells11071160] [Reference Citation Analysis]
39 Hussain Z, Nigri J, Tomasini R. The Cellular and Biological Impact of Extracellular Vesicles in Pancreatic Cancer. Cancers (Basel) 2021;13:3040. [PMID: 34207163 DOI: 10.3390/cancers13123040] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Yang C, Li J, Guo Y, Gan D, Zhang C, Wang R, Hua L, Zhu L, Ma P, Shi J, Li S, Su H. Role of TFRC as a Novel Prognostic Biomarker and in Immunotherapy for Pancreatic Carcinoma. Front Mol Biosci 2022;9:756895. [DOI: 10.3389/fmolb.2022.756895] [Reference Citation Analysis]
41 Hung YH, Chen LT, Hung WC. The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy. Biomedicines 2022;10:926. [PMID: 35453676 DOI: 10.3390/biomedicines10040926] [Reference Citation Analysis]
42 Niland S, Eble JA. Hold on or Cut? Integrin- and MMP-Mediated Cell-Matrix Interactions in the Tumor Microenvironment. Int J Mol Sci 2020;22:E238. [PMID: 33379400 DOI: 10.3390/ijms22010238] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]